GSK (GSK) Scheduled to Post Earnings on Wednesday

GSK (NYSE:GSK - Get Free Report) will announce its earnings results before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $0.95 per share for the quarter. GSK has set its FY 2024 guidance at 1.640-1.690 EPS.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.04). GSK had a return on equity of 51.45% and a net margin of 16.24%. The company had revenue of $10 billion during the quarter, compared to analysts' expectations of $9.79 billion. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

GSK Stock Down 0.9 %

GSK traded down $0.36 during midday trading on Wednesday, reaching $40.88. The company's stock had a trading volume of 1,816,110 shares, compared to its average volume of 3,448,385. GSK has a 1 year low of $33.33 and a 1 year high of $43.84. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 1.19. The stock's 50-day moving average is $41.86 and its 200-day moving average is $38.91. The firm has a market capitalization of $84.72 billion, a price-to-earnings ratio of 13.58, a PEG ratio of 1.43 and a beta of 0.64.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd were given a $0.3564 dividend. This is a positive change from GSK's previous quarterly dividend of $0.34. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a $1.43 dividend on an annualized basis and a yield of 3.49%. GSK's payout ratio is 52.82%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on GSK shares. Morgan Stanley assumed coverage on GSK in a research note on Tuesday, January 23rd. They set an "equal weight" rating for the company. Citigroup upgraded shares of GSK from a "neutral" rating to a "buy" rating in a report on Tuesday, February 13th. Jefferies Financial Group raised shares of GSK from a "hold" rating to a "buy" rating in a research note on Wednesday, January 3rd. Finally, Guggenheim upgraded GSK from a "neutral" rating to a "buy" rating in a report on Monday, March 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy".

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.